Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice-Reference-Cited by-同舟云学术

Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice

Published:2019-06-17 Issue:6 Volume:14 Page:e0218096
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Arakawa Kentaro,Ishigami Tomoaki^ORCID,Nakai-Sugiyama Michiko,Chen Lin,Doi Hiroshi,Kino Tabito,Minegishi Shintaro,Saigoh-Teranaka Sae,Sasaki-Nakashima Rie,Hibi Kiyoshi,Kimura Kazuo,Tamura Kouichi

Funder

Ministry of Education, Culture, Sports, Science and Technology

Yokohama City

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference49 articles.

1. Atherosclerosis—an immune disease: The Anitschkov Lecture 2007;GK Hansson;Atherosclerosis,2009

2. Inflammation in atherosclerosis;P Libby;Nature,2002

3. Commensal microbe-specific activation of B2 cell subsets contributes to atherosclerosis development independently of lipid metabolism;L Chen;EBioMedicine,2016

4. Anti-interleukin-5 and multiple autoantibodies are associated with human atherosclerotic diseases and serum interleukin-5 levels;T Ishigami;FASEB J,2013

5. The intestinal barrier and its regulation by neuroimmune factors;AV Keita;Neurogastroenterol Motil,2010

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response to Letter to the Editor: “Same condition treated with the same drug in the same daily dose but a different response—Why?”;Journal of Pediatric Gastroenterology and Nutrition;2024-04-09

2. Intestinal mucosal barrier: a potential target for traditional Chinese medicine in the treatment of cardiovascular diseases;Frontiers in Pharmacology;2024-02-26

3. Efficacy of lactulose supplementation as a preventive measure for cardiovascular events post myocardial infarction: a preliminary retrospective study;2023-08-03

4. Alleviation of cholestatic liver injury and intestinal permeability by lubiprostone treatment in bile duct ligated rats: role of intestinal FXR and tight junction proteins claudin-1, claudin-2, and occludin;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-03-10

5. The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn’s Disease but Not Ulcerative Colitis Patients;Pharmaceutics;2023-03-02